Despite a challenging global funding climate, the Swiss life sciences sector is not just resilient – it is accelerating.

The Spanish life sciences market is experiencing an unprecedented surge in both capital investment and talent acquisition. With recent domestic announcements including massive €100M+ early-stage venture funds and major institutional targets aiming for €300M in biotech investments by 2030, Spain has firmly solidified its position as a leading European hub for biopharma innovation and commercialisation.

The UK life sciences market is currently operating at a five-year high. Q2 2026 saw venture investment hit a staggering £2.11 billion. Even excluding a historic £1.6 billion mega-round for a London-based AI drug discovery spin-out, baseline venture funding nearly doubled year-on-year.

The Nordic biopharma landscape is experiencing a fascinating divergence. While the entire region remains a global powerhouse for innovation, the data reveals a clear shift: Denmark is rapidly concentrating capital and commercial scale, whilst Sweden remains a highly productive engine for early clinical innovation and M&A.

The DACH region – Germany, Austria, and Switzerland – remains the undisputed powerhouse of the European life sciences ecosystem. Home to thousands of biotechnology, pharmaceutical, and medical technology companies, it is the strategic and operational nerve centre for global biopharma.

Hiring algorithms are now deeply embedded in the job market. The study notes that more than 90% of U.S. employers use automated tools at some stage of screening, which means these systems can significantly shape who gets seen and who does not.

The biopharma sector enters 2026 with real momentum and a renewed sense of urgency. Innovation is scaling again. A significant patent cliff is approaching. And the macro environment, for the first time in several years, is more supportive than restrictive.

The biopharma sector enters 2026 with real momentum and a renewed sense of urgency. Innovation is scaling again. A significant patent cliff is approaching. And the macro environment, for the first time in several years, is more supportive than restrictive.